Tsutomu Hachiya
Overview
Explore the profile of Tsutomu Hachiya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
149
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tateishi K, Mizugaki H, Ikezawa Y, Morita R, Yokoo K, Sumi T, et al.
Jpn J Clin Oncol
. 2024 Dec;
55(3):253-260.
PMID: 39656678
Background: In the first-line treatment of elderly patients with advanced-stage non-small cell lung cancer (NSCLC) with high programmed death-ligand 1 (PD-L1) expression (tumor proportion score ≥ 50%), this study aimed...
2.
Ozawa R, Sonehara K, Hachiya T, Nozawa S, Agatsuma T, Yamamoto H, et al.
Cancer Med
. 2024 Aug;
13(15):e70080.
PMID: 39096117
Introduction: Chemoimmunotherapy is widely used as the first-line management of advanced non-small cell lung cancer (NSCLC) in clinical settings. However, predictive factors associated with the development of immune-related adverse events...
3.
Ikezawa Y, Morita R, Mizugaki H, Tateishi K, Yokoo K, Sumi T, et al.
Cancer Med
. 2024 Jul;
13(14):e70036.
PMID: 39030894
Background: Selecting pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum-based chemotherapy (COMB) for patients with nonsmall cell lung cancer (NSCLC) and high programmed death-ligand 1 (PD-L1) expression is an important issue...
4.
Yazaki T, Kimoto M, Minagawa A, Maruno T, Yamanaka M, Sonehara K, et al.
Am J Case Rep
. 2024 Jun;
25:e943466.
PMID: 38822519
BACKGROUND Various resistance mechanisms of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) have been reported, and approximately half of the cases show a T790M point mutation as resistance...
5.
Hirabayashi T, Sonehara K, Ozawa R, Hachiya T, Nozawa S, Agatsuma T, et al.
Oncology
. 2024 Feb;
102(10):819-827.
PMID: 38320539
Introduction: Combination therapy of anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibodies and platinum-based chemotherapy has been widely used as a first-line treatment for patients with unresectable...
6.
Ikezawa Y, Mizugaki H, Morita R, Tateishi K, Yokoo K, Sumi T, et al.
Cancer Sci
. 2022 Apr;
113(6):2109-2117.
PMID: 35377496
It is not clear whether pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum-based chemotherapy (COMB) should be selected for patients with advanced non-small-cell lung cancer (NSCLC) exhibiting high PD-L1 expression (tumor...
7.
Goto N, Wada Y, Ikuyama Y, Akahane J, Kosaka M, Ushiki A, et al.
J Infect Chemother
. 2021 Aug;
27(12):1706-1712.
PMID: 34412984
Introduction: Risk factors for seriously ill coronavirus disease 19 (COVID-19) patients have been reported in several studies. However, to date, few studies have reported simple risk assessment tools for distinguishing...
8.
Akahane J, Ushiki A, Kosaka M, Ikuyama Y, Matsuo A, Hachiya T, et al.
J Infect Chemother
. 2020 Dec;
27(5):707-714.
PMID: 33376033
Introduction: There is an increasing incidence of Pneumocystis pneumonia (PcP) among individuals without human immunodeficiency virus (HIV) infection (non-HIV PcP). However, prognostic factors for patients with non-HIV PcP have not...
9.
Tanaka S, Hirabayashi T, Kimoto M, Hama M, Hachiya T, Gomi K
Intern Med
. 2020 Nov;
60(7):1073-1076.
PMID: 33162476
We herein report a rare case of advanced lung adenocarcinoma with central diabetes insipidus due to pituitary metastasis. Although treatment with gefitinib was dramatically effective, the symptoms of diabetes insipidus...
10.
Sonehara K, Kobayashi T, Tateishi K, Morozumi N, Yoshiike F, Hachiya T, et al.
Thorac Cancer
. 2019 Apr;
10(5):1078-1085.
PMID: 31006178
Background: In the LUX-Lung 3 and LUX-Lung 6 trials, afatinib improved overall survival in previously untreated patients with EGFR 19del mutated non-small cell lung cancer (NSCLC) compared to chemotherapy. The...